Home / Latest Reports / Hiv Drugs Market

HIV Drugs Market by Medication Class - Global Industry Analysis & Forecast to 2027

Published On : June 2022 Pages : 180 Category: Pharma & Healthcare Report Code : HC063925

SEGMENTS & REGIONS:

  • Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa

HIV Drugs Market by Medication Class (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), Entry Inhibitors, Multi-Class Combination Drugs, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors (FI), HIV Integrase Stand Transfer Inhibitors)   - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The HIV Drugs Market have encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Globally, there are very high prevalence of individuals dealing with HIV due to the several factors, such as lacking availability of drugs for the treatment of HIV infection. In the upcoming nations such as sub-Saharan Africa, countries that have low income do not have sufficient funds to purchase high price drugs leading to increase in the population suffering with HIV.

Drivers and Restraints

The main aspects that boost the HIV drug market development incorporate increment in pervasiveness of HIV and ascend in treatment and determination rate. Also, there is an expansion in the administration activity to build mindfulness among individuals about HIV cause, side effects, accessible treatment choices, and the urgent job of these medications in the control of HIV infection development.

Regional Insights

North America was the most substantial income contributor in 2017; this is credited to the awareness about medicinal services in North America.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Merck & Co., Inc.
  • AbbVie
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Boehringer Ingelheim International GmbH
  • ViiV Healthcare
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb
  • Johnson & Johnson

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         HIV Drugs Market, By Medication Class, Estimates and Forecast, 2017-2027 ($Million)

o    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

o    Protease Inhibitors (PIs)

o    Entry Inhibitors

o    Multi-Class Combination Drugs

o    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

o    Fusion Inhibitors (FI)

o    HIV Integrase Stand Transfer Inhibitors

·         HIV Drugs Market, By Key Players

o    Merck & Co., Inc.

o    AbbVie

o    Teva Pharmaceutical Industries Ltd.

o    Cipla Limited

o    Boehringer Ingelheim International GmbH

o    ViiV Healthcare

o    F. Hoffmann-La Roche Ltd.

o    Bristol-Myers Squibb

o    Johnson & Johnson

·         HIV Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America HIV Drugs Market, By Country

o    U.S. HIV Drugs Market

o    Canada HIV Drugs Market

o    Mexico HIV Drugs Market

o    Europe

§  Europe HIV Drugs Market, By Country

o    Germany HIV Drugs Market

o    UK HIV Drugs Market

o    France HIV Drugs Market

o    Russia HIV Drugs Market

o    Italy HIV Drugs Market

o    Rest of Europe HIV Drugs Market

o    Asia-Pacific

§  Asia-Pacific HIV Drugs Market, By Country

o    China HIV Drugs Market

o    Japan HIV Drugs Market

o    South Korea HIV Drugs Market

o    India HIV Drugs Market

o    Southeast Asia HIV Drugs Market

o    Rest of Asia-Pacific HIV Drugs Market

o    South America

§  South America HIV Drugs Market

o    Brazil HIV Drugs Market

o    Argentina HIV Drugs Market

o    Columbia HIV Drugs Market

o    Rest of South America HIV Drugs Market

o    Middle East and Africa

§  Middle East and Africa HIV Drugs Market

o    Saudi Arabia HIV Drugs Market

o    UAE HIV Drugs Market

o    Egypt HIV Drugs Market

o    Nigeria HIV Drugs Market

o    South Africa HIV Drugs Market

o    Rest of MEA HIV Drugs Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       HIV Drugs Market, By Medication Class

5.1.     Introduction

5.2.     Global HIV Drugs Revenue and Market Share by Medication Class (2017-2027)

5.2.1.  Global HIV Drugs Revenue and Revenue Share by Medication Class (2017-2027)

5.3.     Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

5.3.1.  Global Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Revenue and Growth Rate (2017-2027)

5.4.     Protease Inhibitors (PIs)

5.4.1.  Global Protease Inhibitors (PIs) Revenue and Growth Rate (2017-2027)

5.5.     Entry Inhibitors

5.5.1.  Global Entry Inhibitors Revenue and Growth Rate (2017-2027)

5.6.     Multi-Class Combination Drugs

5.6.1.  Global Multi-Class Combination Drugs Revenue and Growth Rate (2017-2027)

5.7.     Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

5.7.1.  Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Revenue and Growth Rate (2017-2027)

5.8.     Fusion Inhibitors (FI)

5.8.1.  Global Fusion Inhibitors (FI) Revenue and Growth Rate (2017-2027)

5.9.     HIV Integrase Stand Transfer Inhibitors

5.9.1.  Global HIV Integrase Stand Transfer Inhibitors Revenue and Growth Rate (2017-2027)

6.       HIV Drugs Market, By Region

6.1.     Introduction

6.2.     Global HIV Drugs Revenue and Market Share by Regions

6.2.1.  Global HIV Drugs Revenue by Regions (2017-2027)

6.3.     North America HIV Drugs by Countries

6.3.1.  North America HIV Drugs Revenue and Growth Rate (2017-2027)

6.3.2.  North America HIV Drugs Revenue (Million USD) by Countries (2017-2027)

6.3.3.  United States

6.3.3.1.  United States HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.4.  Canada

6.3.4.1.  Canada HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.5.  Mexico

6.3.5.1.  Mexico HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.     Europe HIV Drugs by Countries

6.4.1.  Europe HIV Drugs Revenue and Growth Rate (2017-2027)

6.4.2.  Europe HIV Drugs Revenue (Million USD) by Countries (2017-2027)

6.4.3.  Germany

6.4.3.1.  Germany HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.4.  France

6.4.4.1.  France HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.5.  UK

6.4.5.1.  UK HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.6.  Russia

6.4.6.1.  Russia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.7.  Italy

6.4.7.1.  Italy HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.8.  Rest of Europe

6.4.8.1.  Rest of Europe HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.     Asia-Pacific HIV Drugs by Countries

6.5.1.  Asia-Pacific HIV Drugs Revenue and Growth Rate (2017-2027)

6.5.2.  Asia-Pacific HIV Drugs Revenue (Million USD) by Countries (2017-2027)

6.5.3.  China

6.5.3.1.  China HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.4.  Japan

6.5.4.1.  Japan HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.5.  Korea

6.5.5.1.  Korea HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.6.  India

6.5.6.1.  India HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.7.  Southeast Asia

6.5.7.1.  Southeast Asia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.8.  Rest of Asia-Pacific

6.5.8.1.  Rest of Asia-Pacific HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.     South America HIV Drugs by Countries

6.6.1.  South America HIV Drugs Revenue and Growth Rate (2017-2027)

6.6.2.  South America HIV Drugs Revenue (Million USD) by Countries (2017-2027)

6.6.3.  Brazil

6.6.3.1.  Brazil HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.4.  Argentina

6.6.4.1.  Argentina HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.5.  Columbia

6.6.5.1.  Columbia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.6.  Rest of South America

6.6.6.1.  Rest of South America HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.     Middle East and Africa HIV Drugs by Countries

6.7.1.  Middle East and Africa HIV Drugs Revenue and Growth Rate (2017-2027)

6.7.2.  Middle East and Africa HIV Drugs Revenue (Million USD) by Countries (2017-2027)

6.7.3.  Saudi Arabia

6.7.3.1.  Saudi Arabia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.4.  United Arab Emirates

6.7.4.1.  United Arab Emirates HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.5.  Egypt

6.7.5.1.  Egypt HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.6.  Nigeria

6.7.6.1.  Nigeria HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.7.  South Africa

6.7.7.1.  South Africa HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.8.  Turkey

6.7.8.1.  Turkey HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.  Rest of Middle East and Africa HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

7.       Company Profiles

7.1.     Merck & Co., Inc.

7.1.1.  Business Overview

7.1.2.   Service Portfolio

7.1.3.  Strategic Developments

7.1.4.  Financial Overview

7.2.     AbbVie

7.2.1.  Business Overview

7.2.2.   Service Portfolio

7.2.3.  Strategic Developments

7.2.4.  Financial Overview

7.3.     Teva Pharmaceutical Industries Ltd.

7.3.1.  Business Overview

7.3.2.   Service Portfolio

7.3.3.  Strategic Developments

7.3.4.  Financial Overview

7.4.     Gilead Sciences, Inc.

7.4.1.  Business Overview

7.4.2.   Service Portfolio

7.4.3.  Strategic Developments

7.4.4.  Financial Overview

7.5.     Cipla Limited

7.5.1.  Business Overview

7.5.2.   Service Portfolio

7.5.3.  Strategic Developments

7.5.4.  Financial Overview

7.6.     Boehringer Ingelheim International GmbH

7.6.1.  Business Overview

7.6.2.   Service Portfolio

7.6.3.  Strategic Developments

7.6.4.  Financial Overview

7.7.     ViiV Healthcare

7.7.1.  Business Overview

7.7.2.   Service Portfolio

7.7.3.  Strategic Developments

7.7.4.  Financial Overview

7.8.     F. Hoffmann-La Roche Ltd.

7.8.1.  Business Overview

7.8.2.   Service Portfolio

7.8.3.  Strategic Developments

7.8.4.  Financial Overview

7.9.     Bristol-Myers Squibb

7.9.1.  Business Overview

7.9.2.   Service Portfolio

7.9.3.  Strategic Developments

7.9.4.  Financial Overview

7.10. Johnson & Johnson

7.10.1.      Business Overview

7.10.2.       Service Portfolio

7.10.3.      Strategic Developments

7.10.4.      Financial Overview

8.       HIV Drugs Market Forecast (2017-2027)

8.1.     Global HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2027)

8.2.     HIV Drugs Market Forecast by Regions (2017-2027)

8.2.1.  North America HIV Drugs Market Forecast (2017-2027)

8.2.1.1.  United States HIV Drugs Market Forecast (2017-2027)

8.2.1.2.  Canada HIV Drugs Market Forecast (2017-2027)

8.2.1.3.  Mexico HIV Drugs Market Forecast (2017-2027)

8.2.2.  Europe HIV Drugs Market Forecast (2017-2027)

8.2.2.1.  Germany HIV Drugs Market Forecast (2017-2027)

8.2.2.2.  France HIV Drugs Market Forecast (2017-2027)

8.2.2.3.  UK HIV Drugs Market Forecast (2017-2027)

8.2.2.4.  Russia HIV Drugs Market Forecast (2017-2027)

8.2.2.5.  Italy HIV Drugs Market Forecast (2017-2027)

8.2.2.6.  Rest of Europe HIV Drugs Market Forecast (2017-2027)

8.2.3.  Asia-Pacific HIV Drugs Market Forecast (2017-2027)

8.2.3.1.  China HIV Drugs Market Forecast (2017-2027)

8.2.3.2.  Japan HIV Drugs Market Forecast (2017-2027)

8.2.3.3.  Korea HIV Drugs Market Forecast (2017-2027)

8.2.3.4.  India HIV Drugs Market Forecast (2017-2027)

8.2.3.5.  Southeast Asia HIV Drugs Market Forecast (2017-2027)

8.2.3.6.  Rest of Asia-Pacific HIV Drugs Market Forecast (2017-2027)

8.2.4.  South America HIV Drugs Market Forecast (2017-2027)

8.2.4.1.  Brazil HIV Drugs Market Forecast (2017-2027)

8.2.4.2.  Argentina HIV Drugs Market Forecast (2017-2027)

8.2.4.3.  Columbia HIV Drugs Market Forecast (2017-2027)

8.2.4.4.  Rest of South America HIV Drugs Market Forecast (2017-2027)

8.2.5.  Middle East and Africa HIV Drugs Market Forecast (2017-2027)

8.2.5.1.  Saudi Arabia HIV Drugs Market Forecast (2017-2027)

8.2.5.2.  United Arab Emirates HIV Drugs Market Forecast (2017-2027)

8.2.5.3.  Egypt HIV Drugs Market Forecast (2017-2027)

8.2.5.4.  Nigeria HIV Drugs Market Forecast (2017-2027)

8.2.5.5.  South Africa HIV Drugs Market Forecast (2017-2027)

8.2.5.6.  Turkey HIV Drugs Market Forecast (2017-2027)

8.2.5.7.  Rest of Middle East and Africa HIV Drugs Market Forecast (2017-2027)

8.3.     HIV Drugs Market Forecast by Medication Class (2017-2027)

8.3.1.  HIV Drugs Forecast by Medication Class (2017-2027)

8.3.2.  HIV Drugs Market Share Forecast by Medication Class (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa HIV Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global HIV Drugs Revenue and Revenue Share by Medication Class (2017-2018)
Figure Global Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Revenue and Growth Rate (2017-2018)
Figure Global Protease Inhibitors (PIs) Revenue and Growth Rate (2017-2018)
Figure Global Entry Inhibitors Revenue and Growth Rate (2017-2018)
Figure Global Multi-Class Combination Drugs Revenue and Growth Rate (2017-2018)
Figure Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Revenue and Growth Rate (2017-2018)
Figure Global Fusion Inhibitors (FI) Revenue and Growth Rate (2017-2018)
Figure Global HIV Integrase Stand Transfer Inhibitors Revenue and Growth Rate (2017-2018)
Table Global HIV Drugs Revenue by Regions (2017-2018)
Figure North America HIV Drugs Growth Rate (2017-2018)
Figure North America HIV Drugs Revenue and Growth Rate (2017-2018)
Figure North America HIV Drugs by Countries (2017-2018)
Figure North America HIV Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States HIV Drugs Growth Rate (2017-2018)
Figure United States HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada HIV Drugs Growth Rate (2017-2018)
Figure Canada HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico HIV Drugs Growth Rate (2017-2018)
Figure Mexico HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe HIV Drugs Growth Rate (2017-2018)
Figure Europe HIV Drugs Revenue and Growth Rate (2017-2018)
Figure Europe HIV Drugs by Countries (2017-2018)
Figure Europe HIV Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany HIV Drugs Growth Rate (2017-2018)
Figure Germany HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France HIV Drugs Growth Rate (2017-2018)
Figure France HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK HIV Drugs Growth Rate (2017-2018)
Figure UK HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia HIV Drugs Growth Rate (2017-2018)
Figure Russia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy HIV Drugs Growth Rate (2017-2018)
Figure Italy HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe HIV Drugs Growth Rate (2017-2018)
Figure Rest of Europe HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific HIV Drugs Growth Rate (2017-2018)
Figure Asia-Pacific HIV Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific HIV Drugs by Countries (2017-2018)
Figure Asia-Pacific HIV Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China HIV Drugs Growth Rate (2017-2018)
Figure China HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan HIV Drugs Growth Rate (2017-2018)
Figure Japan HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea HIV Drugs Growth Rate (2017-2018)
Figure Korea HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India HIV Drugs Growth Rate (2017-2018)
Figure India HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia HIV Drugs Growth Rate (2017-2018)
Figure Southeast Asia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific HIV Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America HIV Drugs Growth Rate (2017-2018)
Figure South America HIV Drugs Revenue and Growth Rate (2017-2018)
Figure South America HIV Drugs by Countries (2017-2018)
Figure South America HIV Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil HIV Drugs Growth Rate (2017-2018)
Figure Brazil HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina HIV Drugs Growth Rate (2017-2018)
Figure Argentina HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia HIV Drugs Growth Rate (2017-2018)
Figure Columbia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America HIV Drugs Growth Rate (2017-2018)
Figure Rest of South America HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa HIV Drugs Growth Rate (2017-2018)
Figure Middle East and Africa HIV Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa HIV Drugs by Countries (2017-2018)
Figure Middle East and Africa HIV Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia HIV Drugs Growth Rate (2017-2018)
Figure Saudi Arabia HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates HIV Drugs Growth Rate (2017-2018)
Figure United Arab Emirates HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt HIV Drugs Growth Rate (2017-2018)
Figure Egypt HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria HIV Drugs Growth Rate (2017-2018)
Figure Nigeria HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa HIV Drugs Growth Rate (2017-2018)
Figure South Africa HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey HIV Drugs Growth Rate (2017-2018)
Figure Turkey HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa HIV Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa HIV Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck & Co., Inc. HIV Drugs Financial Overview
Table AbbVie HIV Drugs Financial Overview
Table Teva Pharmaceutical Industries Ltd. HIV Drugs Financial Overview
Table Gilead Sciences, Inc. HIV Drugs Financial Overview
Table Cipla Limited HIV Drugs Financial Overview
Table Boehringer Ingelheim International GmbH HIV Drugs Financial Overview
Table ViiV Healthcare HIV Drugs Financial Overview
Table F. Hoffmann-La Roche Ltd. HIV Drugs Financial Overview
Table Bristol-Myers Squibb HIV Drugs Financial Overview
Table Johnson & Johnson HIV Drugs Financial Overview
Figure Global HIV Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table HIV Drugs Market Forecast by Regions (2018-2025)
Figure North America HIV Drugs Market Forecast (2018-2025)
Figure United States HIV Drugs Market Forecast (2018-2025)
Figure Canada HIV Drugs Market Forecast (2018-2025)
Figure Mexico HIV Drugs Market Forecast (2018-2025)
Figure Europe HIV Drugs Market Forecast (2018-2025)
Figure Germany HIV Drugs Market Forecast (2018-2025)
Figure France HIV Drugs Market Forecast (2018-2025)
Figure UK HIV Drugs Market Forecast (2018-2025)
Figure Russia HIV Drugs Market Forecast (2018-2025)
Figure Italy HIV Drugs Market Forecast (2018-2025)
Figure Rest of Europe HIV Drugs Market Forecast (2018-2025)
Figure Asia-Pacific HIV Drugs Market Forecast (2018-2025)
Figure China HIV Drugs Market Forecast (2018-2025)
Figure Japan HIV Drugs Market Forecast (2018-2025)
Figure Korea HIV Drugs Market Forecast (2018-2025)
Figure India HIV Drugs Market Forecast (2018-2025)
Figure Southeast Asia HIV Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific HIV Drugs Market Forecast (2018-2025)
Figure South America HIV Drugs Market Forecast (2018-2025)
Figure Brazil HIV Drugs Market Forecast (2018-2025)
Figure Argentina HIV Drugs Market Forecast (2018-2025)
Figure Columbia HIV Drugs Market Forecast (2018-2025)
Figure Rest of South America HIV Drugs Market Forecast (2018-2025)
Figure Middle East and Africa HIV Drugs Market Forecast (2018-2025)
Figure Saudi Arabia HIV Drugs Market Forecast (2018-2025)
Figure United Arab Emirates HIV Drugs Market Forecast (2018-2025)
Figure Egypt HIV Drugs Market Forecast (2018-2025)
Figure Nigeria HIV Drugs Market Forecast (2018-2025)
Figure South Africa HIV Drugs Market Forecast (2018-2025)
Figure Turkey HIV Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa HIV Drugs Market Forecast (2018-2025)
Figure Global HIV Drugs Forecast by Medication Class (2018-2025)
Figure Global HIV Drugs Market Share Forecast by Medication Class (2018-2025)
Figure Global HIV Drugs Forecast by Medication Class (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

Request Sample Enquire Before Buying Request for Customization

Request Sample